Our group has expertise in integrating multi-omics profiling and clinical information from cancer patients using mathematical and statistical approaches such as machine learning and network modeling. The medical aim is to optimize treatment outcomes for individual patients using maximally predictive models and minimal biomarker signatures that enable real-time and cost-effective routine diagnostics and prognosis. We believe that combining functional, molecular and genomic profiling information is critical for next-generation precision medicine applications, where integrative modeling and clever use of big data will pinpoint effective and selective targets for personalized therapies.

1. Zhi Zhao, John Zobolas, Manuela Zucknick, Tero Aittokallio. Tutorial on survival modeling with applications to omics data , Bioinformatics , Volume 40, Issue 3, March 2024, btae132. doi: 10.1093/bioinformatics/btae132
2. Yingjia Chen, Liye He, Aleksandr Ianevski, Pilar Ayuda-Durán, Swapnil Potdar, Jani Saarela, Juho J. Miettinen, Sari Kytölä, Susanna Miettinen, Mikko Manninen, Caroline A. Heckman, Jorrit M. Enserink, Krister Wennerberg & Tero Aittokallio.  Robust scoring of selective drug responses for patient-tailored therapy selection .   Nat Protoc  19 , 60–82 (2024) doi: 10.1038/s41596-023-00903-x
3. Zhao Z, Wang S, Zucknick M, Aittokallio T. Tissue-specific identification of multi-omics features for pan-cancer drug response prediction . iScience 2022;25:104767. doi: 10.1016/j.isci.2022.104767
4. Ianevski A, Giri AK, Aittokallio T. Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data . Nat Commun  13 , 1246 (2022). http://doi.org/10.1038/s41467-022-28803-w.
5. Ianevski A, Lahtela J, Javarappa KK, Sergeev P, Ghimire BR, Gautam P, Vähä-Koskela M, Turunen L, Linnavirta N, Kuusanmäki H, Kontro M, Porkka K, Heckman CA, Mattila P, Wennerberg K, Giri AK, Aittokallio T.  Patient-tailored design for selective co-inhibition of leukemic cell subpopulations . Sci. Adv. 7 , eabe4038 (2021). doi: 10.1126/sciadv.abe4038